Read More

Intellia Therapeutics Highlights Its 3-Year Strategic Priorities And Anticipated 2024 Key Milestones; Ended 2023 In A Strong Financial Position With Approximately $1B In Cash; Cash Runway Extended Into Mid-2026

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in vivo gene insertion

NTLA